ILK and ovarian carcinoma: In ovarian cancer, TGM2 interacts and activates the integrin-linked kinase (ILK) through phosphorylation at ILK Ser246, which subsequently activates β-catenin through the phosphorylation of glycogen synthase kinase-3α/β (GSK3α/β) [36].